PremiumCompany AnnouncementsLineage Cell Therapeutics Reports Q1 2025 Financials Lineage Cell Therapeutics reports Q1 EPS (2c), consensus (3c) Lineage Cell announces 36-month results for Phase 1/2a trial of RG6501 PremiumCompany AnnouncementsLineage Cell Therapeutics’ Earnings Call: Progress Amid Challenges Lineage Cell Therapeutics: 2024 Financial Results and Strategic Progress Options Volatility and Implied Earnings Moves Today, March 10, 2025 PremiumThe FlyLineage Cell Therapeutics initiates study of OPC1 for spinal injury Lineage Therap Secures $66M Funding Through Direct Offering Lineage Cell Therapeutics price target lowered to $3 from $5 at Maxim 
